Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HBV

B cell lymphoma 2
(BCL-2; BCL2); Bcl-xL

Worm and cell culture studies suggest inhibiting BCL2-family proteins could help treat HBV infection. In the Caenorhabditis elegans roundworm, the HBV protein HBx was shown to interact with a BCL2 homolog and triggered both necrotic and apoptotic cell death. In human hepatocyte cells, HBx bound to BCL2 and Bcl-xL and triggered cell death. In hepatocytes, small hairpin RNA against BCL2 or Bcl-xL led to less HBV DNA replication than control shRNA. Next steps could include evaluating pharmacological inhibitors of BCL2-family proteins in models of HBV infection.
At least 13 companies have compounds that target BCL2 family proteins in Phase II testing or earlier to treat various cancers.

SciBX 5(43); doi:10.1038/scibx.2012.1141
Published online Nov. 1, 2012

Patent and licensing status unavailable for findings from both studies

Geng, X. et al. Proc. Natl. Acad. Sci. USA; published online Oct. 22, 2012;
doi:10.1073/pnas.1204668109
Contact: Ding Xue, University of Colorado at Boulder, Boulder, Colo.
e-mail:
ding.xue@colorado.edu

Contact: Ning-Shao Xia, Xiamen University, Xiamen, China
e-mail:
nsxia@xmu.edu.cn


Geng, X. et al. Proc. Natl. Acad. Sci. USA; published online Oct. 22, 2012;
doi:10.1073/pnas.1204652109
Contact: Ding Xue, University of Colorado at Boulder, Boulder, Colo.
e-mail:
ding.xue@colorado.edu